ArticleESMO open2023
Controversies in NSCLC: which second-line strategy after chemo-immunotherapy?
L Moliner et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
16 papers cite it
this papertrialcites it
ArticleESMO open2023
L Moliner et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.